News and Trends 5 Sep 2022
Sanofi and Regeneron’s Dupixent shows sustained improvement in lung function in children
A maintenance therapy from Sanofi and Regeneron, added to other asthma medications, has shown sustained improvement in lung function, low-rate of asthma attacks and a consistent safety profile for up to two years in children. Results from the longest global phase 3 open-label extension trial in the age group six to 11 years old with […]